Plus Therapeutics, Inc. (PSTV)
NASDAQ: PSTV · Real-Time Price · USD
0.3483
+0.0228 (7.00%)
At close: Jun 9, 2025, 4:00 PM
0.3409
-0.0074 (-2.12%)
Pre-market: Jun 10, 2025, 7:53 AM EDT
Plus Therapeutics Employees
Plus Therapeutics had 21 employees as of December 31, 2024. The number of employees increased by 1 or 5.00% compared to the previous year.
Employees
21
Change (1Y)
1
Growth (1Y)
5.00%
Revenue / Employee
$247,905
Profits / Employee
-$1,291,333
Market Cap
5.92M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
PSTV News
- 10 days ago - Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights - GlobeNewsWire
- 17 days ago - Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q - GlobeNewsWire
- 27 days ago - Plus Therapeutics' REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM) - GlobeNewsWire
- 4 weeks ago - Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference - GlobeNewsWire
- 6 weeks ago - Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors - GlobeNewsWire
- 2 months ago - Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases - GlobeNewsWire
- 2 months ago - Plus Therapeutics, Inc. (PSTV) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewsWire